

### **Grace Aouad McComsey, M.D.**

**office: 216-844-3645**

**fax: 216-844-8362**

**email: [mccomsey.grace@clevelandactu.org](mailto:mccomsey.grace@clevelandactu.org)**

#### **EDUCATION**

Undergraduate:	1979 –1982	Mont La Salle College, Beirut, Lebanon, French Baccalaureate in Mathematics
Medical School:	1982- 1989	St. Joseph University, Beirut, Lebanon, M.D.
Postgraduate:	1989-1990	Pediatric Internship, St. George Hospital, Beirut, Lebanon
	1990-1991	Internship, Medicine/Pediatrics, Seton Hall University, St. Joseph's and Medical Center, Patterson, N.J.
	1991-1994	Medicine/Pediatrics Residency, Metrohealth Medical Center, Cleveland, OH
	1994-1997	Fellowship, Combined Adult and Pediatric Infectious Diseases, Case Western Reserve University School of Medicine, Cleveland, OH

#### **CERTIFICATION:**

American Board of Pediatrics: 1994- Recertified 2001

American Board of Internal Medicine: 1994

American Board of Pediatric Infectious Diseases: 1997

American Board of Infectious Disease: 1997

**MEDICAL LICENSE:** OHIO                      1992-present                      3506-4769

#### **HOSPITAL APPOINTMENTS**

7/2004	Associate Professor of Pediatrics and Medicine, Case Western Reserve University, Cleveland, OHIO
5/2004-	Division Chief and Fellowship Program Director, Pediatric Infectious Diseases and Rheumatology, Rainbow Babies and Children's Hospital
7/99-4/04	Clinical Director and Fellowship Program Director, Division of Pediatric Infectious

Diseases, Rainbow Babies and Children's Hospital

12/97-present Assistant Professor of Pediatrics and Medicine, Case Western Reserve University, Cleveland, OHIO

### **PROFESSIONAL MEMBERSHIPS**

Infectious Disease Society of America

Pediatric Infectious Disease Society of America

HIV Medicine Association of the Infectious Diseases Society of America

International AIDS Society

### **HOSPITAL AND DEPARTMENT COMMITTEES**

2001- 2003 Appointments, Promotions and Tenure Committee, Department of Pediatrics

2000- present Education Committee, Department of Pediatrics

2000- present Intern Selection Committee, Medicine/Pediatrics

2001- present Intern Selection Committee, Pediatrics

### **NATIONAL COMMITTEES**

2000 Mitochondrial Dysfunction Study Group of the AIDS Clinical Trials Group

2002- 2003 Pharmacology Committee of the AIDS Clinical Trials Group

2002 Complications of HIV Disease Research Agenda Committee of the AIDS Clinical Trials Group

2003 Women's Health Committee of the Adult Clinical Trials Group

2003 Cardiovascular Disease Focus Group of the Adult Clinical Trials Group

2003 Consultant, Site Review of General Clinical Research Center, National Institute of Health

2003-2004 Member, Metabolic Complications Committee of the AIDS Clinical Trials Group

2004 Vice-Chair, Metabolic Complications Committee of the AIDS Clinical Trials Group

2004 Consultant, Scientific Expert Reviewer, National Institute of Health

### **RESEARCH AWARDS**

Research paper voted *One of 6 best articles in basic science* for “Best of AIDS 2003”

## GRANTS RECEIVED

### 1) NIH funded studies:

R01 AI060484-01A1                      Role of Mitochondria in HIV Lipoatrophy  
 PI: McComsey Grace                      \$2,269,072  
 12/1/04-11/30/09 (tentative)

R21 AI060484-01A1                      Role of Mitochondria in HIV Lipoatrophy  
 PI: McComsey Grace                      \$191,250  
 08/01/2004 - 07/31/2005  
 Bridge funding for the above grant

“Randomized trial of alendronate in HIV-associated osteoporosis,” *Protocol Chair*, Grace McComsey, M.D., ACTG 5163

“Long-term metabolic assessments in subjects treated with ABC/3TC or TDF/FTC along with either efavirenz or ATV/RTV”, *Protocol Chair*, ACTG5224s

“Investigation of non-invasive markers of mitochondrial toxicity,” *Protocol Chair*, Grace McComsey, M.D., ACTG 5144

“Antiretroviral-induced metabolic complications in pregnancy,” Co-investigator, ACTG 5084

“B vitamins in HIV-associated mitochondrial toxicity,” Co-investigator, ACTG 5129

### 2) Funding outside NIH/ACTG (*only studies with McComsey as PI are cited*)

“Characterization of lipodystrophy syndrome in HIV,” PI Grace McComsey, M.D., BTG Pharmaceuticals, 1999-2002

“Simplification of antiretroviral therapy in children,” PI McComsey, Dupont Pharmaceuticals, 1999-2002

“Response to immunization in HIV-infected children,” PI Grace McComsey, Dupont Pharmaceuticals, 2000-2002

“Reversibility of mitochondrial toxicity after antiretroviral switches,” PI Grace McComsey, M.D., GlaxoSmithKline, 2000-2003

“Natural history of hyperlactatemia,” PI Grace McComsey, M.D., GlaxoSmithKline, 2000-2004

“Mitochondrial studies in fat and muscle of HIV+ subjects with lipoatrophy,” PI Grace McComsey, M.D., GlaxoSmithKline, 2000-2003

“Antioxidants in lipoatrophy,” PI Grace McComsey, M.D., Campbell Foundation, 2001-2003

Impact of low dose ritonavir on lipid profile,” PI, Pfizer Pharmaceuticals, 2001-2002

“Immunologic predictors of lipoatrophy,” PI Grace McComsey, M.D., Bristol Myers Squibb Co.

2001-2002

“Differential effect of gender on antiretroviral-induced mitochondrial toxicity,” PI Grace McComsey, M.D., Center for AIDS Research, 2002-2003

“Stable isotopes in the study of mitochondrial dysfunction in lipoatrophy,” PI Grace McComsey, M.D., GlaxoSmithKline, 2002-2004

“Oxidative markers in HIV-associated lipoatrophy,” PI Grace McComsey, M.D., Bristol Myers Squibb Co. 2002-2003

“Longitudinal analysis of mitochondrial DNA depletion and mutations in lipoatrophy and hyperlactatemia,” PI Grace McComsey, M.D., Bristol Myers Squibb Co., 2002-2004

“Investigation of dose effect of stavudine on mitochondrial dysfunction,” PI Grace McComsey, M.D., Bristol Myers Squibb Co., 2004-2006

“Uridine supplementation for HIV associated mitochondrial dysfunction and lipoatrophy”, PI Grace McComsey, M.D., Bristol Myers Squibb Co., 2004-2006

## REVIEWER

Annals of Internal Medicine

Antiviral Therapy

AIDS Research and Human Retroviruses

International Journal of Infectious Diseases

JAIDS

Lancet, Infectious Diseases

## PUBLICATIONS (PEER REVIEWED)

Chandy J, **Aouad G**, Brian B, Schreiber J. Successful Meropenem Treatment of Multiply Resistant Pneumococcal Meningitis. *Peds IDJ* 1997; 16(10): 1009-1010

Chien JW, Valdez H, **McComsey GA**, et al. Presence of mutation conferring resistance to Lamivudine in plasma and cerebrospinal fluid in HIV-1-infected patients. *Journal of Acquired Immune Deficiency Syndromes* 1999; 21(4): 277-280

Anthony DD, Askari AD, Wolpaw T and **McComsey GA**. Wegener granulomatosis simulating bacterial endocarditis. *Archives of Internal Medicine* 1999; 159(15):1807-10

Madhun ZT, Arafah BM, **McComsey GA**. Impaired glucose tolerance in HIV-infected patients [letter]. *Ann Intern Med* 1999; 131(9):715-6

Valdez H, Chowdhry TK, Asaad R, Woolley IJ, Davis T, Davidson R, Beinker N, Gripshover BM, Salata RA, **McComsey GA**, Weissman SB, Lederman MM. The Changing Spectrum of HIV Mortality: Analysis of 260 Deaths from 1995-1999. *Clin Infect Dis* 2001;32(10):1487-1493

Patel S and **McComsey GA**. Medical Management of spinal epidural abscesses in children. *International Pediatrics* 2001;16(3):176-181

**McComsey GA**, Whalen CC, Mawhorter S, et al. Randomized, double-blinded, placebo controlled trial to examine the safety and efficacy of corticosteroid therapy in advanced HIV. *AIDS* 2001; 15:321-327

**McComsey GA**, Tan D, Lederman MM, and Wong L-J. Analysis of the entire mitochondrial DNA genome in the peripheral blood lymphocytes of HIV-infected subjects with or without lipoatrophy reveals novel point mutations. *AIDS* 2002; 16(4):513-8

**McComsey GA**, Valdez H, and Lederman MM. Successful maintenance of HIV viral suppression on Efavirenz monotherapy. *International Pediatrics* 2002; 17(2):94-95

**McComsey GA**, and Lederman MM. High doses of riboflavin and thiamine may help in secondary prevention of hyperlactatemia. *AIDS Reader* 2002; 12:222-224

Leonard E and **McComsey GA**. Metabolic complications of antiretroviral therapy in children. *Peds ID J* 2003; 22:77-84

**McComsey GA**, Bhumbra N, Maa J, et al. Impact of Protease Inhibitor Substitution with Efavirenz in HIV-Infected Children: Results of the First Pediatric Switch Study. *Pediatrics* 2003; 111(3): e275-281

**McComsey G**, Southwell H, Gripshover B, Salata R, and Valdez H. Effect of antioxidants on plasma lipids and peripheral fat in HIV-infected subjects with lipoatrophy. *J Acquir Immune Defic Syndr*. 2003 Aug 15;33(5):605-7

**McComsey GA**, Morrow JD. Lipid oxidative markers are significantly increased in lipoatrophy, but not in sustained asymptomatic hyperlactatemia. *J Acquir Immune Defic Syndr*. 2003;34:45-49

**McComsey G**, Maa JF. Host factors may be more important than the choice of antiretrovirals in the development of lipoatrophy. *AIDS Reader* 2003; 13(11):539-559

**McComsey GA**, Ward DJ, Hessenthaler SM, Sension MG, Shalit P, Lonergan T, Fisher RL, Williams VC, and Hernandez JE, for the TARHEEL Study Team. Regression of HAART-associated lipoatrophy in HIV-infected patients switched from stavudine to abacavir or zidovudine. *Clinical Infectious Diseases* 2004; 38:263-270

**McComsey GA**, Yau L. Asymptomatic Hyperlactatemia: Predictive Value, Natural History and Correlates. *Antiviral Therapy* 2004;9:205-212

Piliero PJ and **McComsey GA**. Buffalo hump: what the experts suggest. *AIDS Clin Care* 2004;16(3):22-23

Wohl DA, Pilcher CD, Revuelta R, **McComsey G**, Yang Y, Evans S, Zackin R, Alston B, Welch S, Basar M, Kashuba A, Kondo P, Martinez A, Giardini J, Quinn J, Littles M, Wingfield H, and Koletar SL for the Adult AIDS Clinical Trials Group A5129 Team. Absence of Sustained Hyperlactatemia in HIV-Infected Patients with Risk Factors for Mitochondrial Toxicity. *JAIDS* 2004;35(3):274-278

**McComsey Grace** and J. Tyler Lonergan. Mitochondrial Dysfunction: Patient Monitoring and Toxicity Management. *JAIDS* 2004; 37:S30-35

Lonergan TJ, **McComsey GA**, Fisher RL, et al. Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine. (In press, *JAIDS* 2004)

**McComsey G**, Williams V, Ward D, Hernandez J. Modifying antiretroviral therapy to alleviate lipoatrophy. (In press, Contagion 2004)

**McComsey GA**, Paulsen DM, Lonergan TJ, Hessenthaler SM, Hoppel CL, Williams VC, Fisher RL, Cherry CL, White-Owen C, Thompson KA, Ross ST, Hernandez JE, and Ross LL. Improvements in Lipoatrophy, Mitochondrial DNA Content and Adipose Tissue Apoptosis Levels after Replacement of Stavudine with either Abacavir or Zidovudine. (In press, AIDS 2004)

**McComsey GA**, Huang JS, Wooley I, Young B, Sax P, Gerber M, Swindells S, Bonilla H, Gopalakrishnan G. Fragility fractures in HIV-infected subjects: Need for better understanding of pathogenesis, diagnosis and management. (In press, The Journal of the International Association of Physicians in AIDS Care, 2004)

Loupa C, Rodriguez B, Valdez H, Salata RA, **McComsey G**, Gripshover B, Fulton S, Lisgaris M, Kucia M, Asaad R, Cline J, Lederman MM. New entrants to HIV care are presenting only at marginally earlier stages of disease but may increasingly represent groups perceived at lower risk. (Submitted, JAIDS 2004)

Cherry CL, Lal L, Thompson KA, McLean CA, Ross LL, Hernandez J, Wesselingh SL, and **McComsey G**. Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patients from stavudine to abacavir or zidovudine. (Submitted JAIDS 2004)

#### **INVITED REVIEW**

**Grace McComsey**. Update on mitochondrial toxicity of antiretrovirals and its link to lipodystrophy. AIDS Reviews 2002; 4:140-147

**Grace A. McComsey** and Ethan Leonard. Metabolic complications of HIV therapy in children. AIDS 2004; 18: 1-16

**Grace A. McComsey** and Ulrich A. Walker. Mitochondria and HIV lipoatrophy. In press, Mitochondrion 2004

#### **NON-PEER REVIEW PUBLICATIONS**

Complications of HIV therapy: A year in review; 2002. CME monogram for national distribution. Sponsored by Rush-Presbyterian-St. Luke's Medical Center, March 2003

The Role of New Protease Inhibitors in Anti-HIV Therapy: Examining Issues of Potency. CME monogram for national distribution. Sponsored by the University of Colorado School of Medicine, April 2003

The Role of New Protease Inhibitors in Anti-HIV Therapy: Examining Issues of Resistance and Sequencing: CME monogram for national distribution. May 03

The Role of New Protease Inhibitors in Anti-HIV Therapy: Examining Issues of Tolerability and Safety: CME monogram for national distribution. July 03

Revitalizing the Protease Inhibitor Class: CME monogram for National Distribution, release date: Sept 03

Strategic Sequencing of Nucleoside Reverse Transcriptase Inhibitors. Designing Initial Therapy to Maximize Long-term Success. CME monogram for national distribution. Sponsored by Rush-Presbyterian-St. Luke's Medical Center, Oct 2003

**ABSTRACTS PRESENTATIONS AT NATIONAL AND INTERNATIONAL MEETINGS**

Johnson R, Lederman M, **Aouad Grace**, and Walker Courtney. Predictors of Ritonavir tolerance in HIV disease (Poster). The 4<sup>th</sup> cfr on Retroviruses and Opportunistic Infections at Washington D.C. January 1997

**McComsey G**, Whalen CC, Mawhorter S, et al. Placebo-controlled trial of prednisone in advanced HIV infection. (Poster 410). The Infectious Diseases Society of America Meeting, Philadelphia, PA, November 18-21, 1999

Patel S and **McComsey GA**. Medical Management of Spinal Epidural Abscesses in children (Poster). The Infectious Diseases Society Meeting, New Orleans 2000

Berger D, **McComsey G**, Shaker-Irwin L, et al. Fat Redistribution Syndrome (FRS) / Lipodystrophy In Women; Sub-Analysis of a Multicenter US Study. (Poster). The 2<sup>nd</sup> International Workshop on Adverse Drug and Lipodystrophy, Toronto Sept 13-15, 2000

**McComsey G**, Shaker-Irwin L, Follansbee S, et al. Fat Redistribution Syndrome / Lipodystrophy and Anabolic Agents: Results of a Large Multicenter US Study. (Poster). The 2<sup>nd</sup> International Workshop on Adverse Drug and Lipodystrophy, Toronto Sept 13-15, 2000

Southwell H, Valdez H, Gripshover H, **McComsey G**, et al. Use of Alternative Therapy among HIV-Infected Patients at an Urban Tertiary Center (Poster). Presented at the 8<sup>th</sup> Retrovirus and Opportunistic Infectious Conference, Chicago, IL, Feb 2001

**McComsey G**, Alvarez A, Joseph J, et al. Is Simplification of HAART safe in HIV-Infected Children? First Pediatric Switch Study (Poster 679). Presented at the 8<sup>th</sup> Retrovirus and Opportunistic Infectious Conference, Chicago, IL, Feb 2001

Patel S, and **McComsey G**. The association of bone mineral density to triglyceride, cholesterol, and lactic acid levels in vertically HIV-infected children receiving HAART (Poster 785). The 39<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America, San Francisco, California, October 2001

Lonergan T, **McComsey G**, Fisher R, et al. Improvements in symptomatic hyperlactatemia are observed after 12 weeks when stavudine is replaced by either abacavir or zidovudine (Poster). The 3<sup>rd</sup> International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Athens, Greece, October 2001

**McComsey G**, Antosh D, and Chu A. Comparison of lipid profiles on nelfinavir- versus lopinavir/ritonavir-containing regimen (Poster). The 3<sup>rd</sup> International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Athens, Greece, October 2001

**McComsey G**, Yau L, Southwell H, et al. Elevated lactate levels are uncommon, even in heavily pretreated HIV-infected subjects (Poster). The 3<sup>rd</sup> International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Athens, Greece, October 2001

**McComsey G, et al. Improvements in Lipoatrophy are Observed After 24 Weeks When Stavudine (d4T) is Replaced by Either Abacavir (ABC) or Zidovudine (ZDV) (Poster). The 9<sup>th</sup> Retrovirus and Opportunistic Infectious Conference, Seattle, WA, Feb 2002**

**McComsey G**, Yau L, Southwell H, et al. Elevated lactate levels are uncommon, even in heavily pretreated HIV-infected subjects; an update of an ongoing longitudinal study (Poster). The 9<sup>th</sup> Retrovirus and Opportunistic Infectious Conference, Seattle, WA, Feb 2002

DM Paulsen, BJ Hill, **G McComsey** and LL Ross. Quantification of Mitochondrial DNA in Human Cells Using Real-Time PCR with Fluorogenic Reporters (Poster). The International World AIDS, Barcelona, Spain, July 2002

**McComsey G**. Effect of ritonavir-boosted protease inhibitor regimens on lipid profiles (Poster). The International World AIDS, Barcelona, Spain, July 2002

Rodriguez B, Valdez H, Gripshover B, **McComsey G**, et al. Opportunistic illnesses in the era of HAART occur despite controlled viral replication and higher CD4 cell counts (Poster). The International World AIDS, Barcelona, Spain, July 2002

**McComsey G**, Ana Alvarez, Nasreen Bhumbra, et al. Significant improvement in metabolic parameters upon substitution of protease inhibitor therapy with Efavirenz in HIV-infected children (Oral presentation). The 42<sup>nd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 2002, San Diego, CA.

**McComsey G**, Ward D, File T, et al. Continued improvements in lipoatrophy are observed through 48 weeks when stavudine is replaced by either abacavir or zidovudine (Poster). The 42<sup>nd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 2002, San Diego, CA..

**McComsey G**, Paulsen D, Lonergan T, et al. Improvements in mitochondrial DNA levels after substituting ABC or ZDV for d4T in HIV-infected patients with lipodystrophy (Poster). The 42<sup>nd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 2002, San Diego, CA..

**McComsey G**, Maa J, Gripshover B, et al. Pretreatment leptin levels may predict risk of lipoatrophy while CD4 cell counts, TNF and on-treatment changes in these indices do not (Poster). The 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 22-25 Sept 2002, San Diego, CA

Yao L, O'Riordan M, Lederman MM, Valdez H, Gripshover B, and **McComsey G**. Lack of significant changes in blood pressure of HIV+ subjects, even after long-term use of PI therapy (Poster). The 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 22-25 Sept 2002, San Diego, CA

**Lonergan T, McComsey G, et al. Lack of recurrence of symptomatic and asymptomatic hyperlactatemia when stavudine (d4T) is replaced by either abacavir (ABC) or zidovudine (ZDV): 48-wk data (Oral). The 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 22-25 Sept 2002, San Diego, CA**

Patel SS, Storer N, and **McComsey G**. Osteoporosis in vertically HIV-infected children receiving HAART (Poster). The Infectious Diseases Society of America Meeting, October 2002, Chicago, IL

Thompson K, **McComsey G**, Paulsen D, et al. Improvements in body fat and mitochondrial (Mt) DNA levels are accompanied by decreased adipose tissue cell apoptosis after replacement of Stavudine (d4T) therapy with either Abacavir (ABC) or Zidovudine (ZDV). (Poster). The 10<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, Boston, MA, Feb 10-14, 2003

**McComsey G** and E Leonard. The effect of calcium and vitamin D on bone mineral density in HIV-infected children with osteoporosis (Poster). The 10<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, Boston, MA, Feb 10-14, 2003

Wohl D, Pilcher C, Revuelta M, **McComsey G**, et al. Absence of Sustained Hyperlactatemia Among HIV-Infected Patients with Risk Factors for Mitochondrial Toxicity (Poster). The 10<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, Boston, MA, Feb 10-14, 2003

**McComsey G**, Williams V, Ward D, et al. Improvement in DEXA- and CT Scan- measured subcutaneous fat after a switch from d4T to abacavir or ZDV do not correlate with anthropometric measurements at 48 weeks. At the 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, July 2003, Paris, France

Ward D, Williams V, **McComsey G**, et al. Baseline lactate levels and CT Scan values predict the regression of lipoatrophy in CT Scan 48 weeks after a switch from stavudine to abacavir or ZDV. At the International AIDS Society meeting, July 2003, Paris, France

**McComsey G**, Yau L. Natural history of sustained hyperlactatemia in HIV-infected subjects. The 43<sup>rd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 2003, Chicago, IL.

**McComsey G**, Morrow J. Lipid oxidative markers are significantly increased in lipoatrophy, but not in sustained asymptomatic hyperlactatemia. The Infectious Diseases Society of America Meeting, October 9-12, 2003, San Diego, CA

**McComsey G**, Paulsen D, Lonergan T, Milano D, Williams V, Pakes G, Cherry K, Hernandez J, and L Ross for the TARHEEL Study Team. Improvements in Body Fat, Mitochondrial DNA Levels and Adipocyte Apoptosis 48 Weeks after Replacement of Stavudine with either Abacavir or Zidovudine Appear Independent of Cellular Cytokine mRNA Levels. *Oral presentation*. The Infectious Diseases Society of America Meeting, October 9-12, 2003, San Diego, CA

Loupa C, Rodriguez B, Valdez H, Salata R, Gripshover B, **McComsey G**, Fulton S, Lisgaris M, Cline J, Kushia M. and Lederman M. New entrants to HIV care are now less likely to have evidence of hepatitis C or B infection or prior STDs. The Infectious Diseases Society of America Meeting, October 9-12, 2003, San Diego, CA

Cherry C, **McComsey G**, Lal L, McLean C, Thompson K, Ross L, and Wesselingh S. Increased adipocyte apoptosis is present in lipoatrophic subjects on d4T and reverses within 48 weeks of switching NRTIs [Abstract 367]. Australian Society for HIV Medicine Annual Meeting, Cairns, October 2003

**McComsey G**, Hoppel C, Williams VC, Lancaster T, Hernandez JE and Ross L<sup>2</sup>. Partial Improvement of Mitochondrial Dysfunction 48 Weeks after Replacement of Stavudine (d4T) with either Abacavir (ABC) or Zidovudine (ZDV). Poster 711. The 11<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Feb 8-11, 2004

**McComsey G**, Huang J, Woolley I, Young B, Sax P, Gerber M, Swindells S, Bonilla H, and Gopalakrishnan G. Fragility Fractures in HIV-Infected Subjects: An Area for Improvement. Poster 743. The 11<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Feb 8-11, 2004

Lisgaris M, Rodríguez B, Salata RA, Gripshover B, **McComsey G**, Fulton S, Lederman M. AIDS Defining Illnesses (ADIs) Develop at More Advanced HIV Stages in HIV-Infected Women than in Men. Poster 951. The 11<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Feb 8-11, 2004

Yadavalli G, Rodriguez B, Lisgaris M, **McComsey G**, Fulton S, Salata R, Gripshover B, and Lederman M. Characteristics of Persons Developing Opportunistic Infections at High CD4 Cell Counts. Poster 765. The 11<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Feb 8-11, 2004

**McComsey G**, Gripshover B, Rodriguez B, Lisgaris M, and Salata R. Lipid and Mitochondrial Oxidative Markers in HIV-infected Subjects with Lipoatrophy. The 11<sup>th</sup> International Congress on Infectious Diseases (International Society for Infectious Diseases Meeting), Cancun, Mexico, March 4-7, 2004

Loupa C, MacKay W, Gripshover B, Lederman M, Salata R, Rodriguez B, Lisgaris M, and **McComsey G**. Determinants of Diabetes in HIV Infected Subjects. The 11<sup>th</sup> International Congress on Infectious Diseases (International Society for Infectious Diseases Meeting), Cancun, Mexico, March 4-7, 2004

Loupa C, Rodriguez B, Valdez H, Salata R, Lisgaris M, Gripshover B, **McComsey G**, Fulton S, and Lederman MM. Gender differences in HIV RNA and CD4 counts, but not in AIDS-defining illnesses and CD4-based HAART initiation threshold, in new entrants to HIV care in Cleveland, Ohio. The 14<sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases, Prague, May 2004

## **PRESENTATIONS AND SEMINARS (NATIONAL AND REGIONAL)**

“Update on Pediatric HIV”. Northern Ohio AIDS Education and Training Center, Jan 7, 2000

“Update on Perinatal HIV”. Annual Neonatal/Perinatal Symposium, St Elizabeth Health Center, Youngstown, OH, April 13, 2000

“Update on Perinatal HIV/ HIV and women”. Northern Ohio AIDS Education & Training Center April 14, 2000

“Update on Metabolic Complications of Antiretroviral Therapy”. Infectious Diseases Grand Rounds, Cleveland Clinic Foundation, Sept 1, 2000

“ABC of lipodystrophy”. CME Meeting Sponsored by Arizona College of Medicine Chicago, IL, Nov 9, 2000

“Anabolic Agents and Lipodystrophy”. CME Meeting sponsored by Arizona College of Medicine, NY, NY, Nov 9, 2000

“HIV in women”. World AIDS Day Symposium. Medical College of Ohio, Toledo Dec 1, 2000

“Metabolic Complications of antiretrovirals”. Grand Rounds, Department of Medicine Fairview General Hospital, May 21, 2001

“Where we are with understanding lipodystrophy?”. Infectious Diseases Grand Rounds Henry Ford Hospital, MI, October 3, 2001

“Long-term complications of HIV and its treatment”. International HIV Seminar hosted by GlaxoSmithKline, Chicago, Illinois, Dec 15, 2001

“Understanding long-term complications of HIV therapy”. Infectious Disease Conference Cleveland Clinic Foundation, Feb 22, 2002

Seminar Chair and Speaker, “Long-term complications of antiretrovirals” Seminar Seattle, WA, Feb 2002

“Do HIV-infected children suffer from complications of HIV therapy?”. Infectious Diseases/Immunology Rounds, Children’s Hospital of Michigan, June 14, 2002

“Lipoatrophy and Mitochondrial Toxicity”. Infectious Diseases Rounds, Tulane University Medical Center, July 18, 2002

“Update on long-term complications of HIV therapy”. AIDS Clinical Trials Unit Seminar  
University of Medicine and Dentistry of New Jersey, July 23, 2002

“Complications of NRTI Therapy”. National Web Conference CME. Sponsored by Rush-Presbyterian-St. Luke’s  
Medical Center, Sept 9, 2002 (2 sessions)

Antiretroviral therapy: update on emerging toxicities”. Infectious Diseases Seminar  
University of Southern California, Los Angeles, CA, Sept 26, 2002

“Mitochondrial Toxicity and Lipoatrophy in HIV Disease”. Advanced Course in Clinical HIV Management: (CME).  
International AIDS Society-USA Seminar in NY. Oct 15, 2002

“Update on long-term complications of HIV and its therapy”. HIV Forum National Seminar  
Chicago, IL, Oct 19, 2002

“Complications of NRTI Therapy”. CME Program for Detroit Infectious Diseases physicians  
Sponsored by Rush-Presbyterian-St. Luke’s Medical Center, Nov 19, 2002

“Update on Antiretroviral Therapy”; Infectious Diseases Grand Round: Henry Ford Hospital  
November 20, 2002

Metabolic complications of antiretroviral therapy; Infectious Diseases Conference (CME)  
UCP Hahnemann University, November 26, 2002

“Update on lipodystrophy and mitochondrial toxicities in HIV”. Infectious Disease Rounds  
Georgetown University, DC, Dec 5, 2002

“Complications of NRTI Therapy”. CME Program for Cleveland Infectious Diseases physicians  
Sponsored by Rush-Presbyterian-St. Luke’s Medical Center, Dec 10, 2002

“Understanding and managing lipodystrophy”, Infectious diseases Rounds  
University of Rochester, Jan 27, 2003

Co-moderator, “Metabolic Complications of HIV”: The 10<sup>th</sup> Retrovirus and Opportunistic Infectious Conference,  
Boston, MA, Feb 13, 2003

“Update on Lipodystrophy and Dyslipidemias in HIV”; St Joseph Medical Center  
Patterson, NJ, March 6, 2003

Challenging of dyslipidemias and lipodystrophy”. Medical College of Ohio, Toledo, Ohio, March 19, 2003

Course Director, CME: “Long-term Complications, Safety and Tolerability”  
75 CME seminars and series of teleconferences. Sponsored by the University of Alabama at Birmingham, 2003

“Understanding Mechanisms and Management of Mitochondrial Toxicity in HIV”. Infectious Diseases Rounds,  
University of Miami, FL, April 4, 2003

“Update on Lipodystrophy and Metabolic Toxicities in HIV”; Medicine Grand Rounds

Mercy Hospital, FL, April 4, 2003

“Lipodystrophy, Mitochondria and HIV”; Infectious Diseases Conference, University of Chicago, April 10, 2003

“ Update on challenges of metabolic complications of HIV”; Combined Adult and Pediatric Infectious Diseases Rounds, University of Jacksonville, Florida; April 22, 2003

“Current understanding of long-term complications of HIV”; Infectious Diseases/ACTG Rounds Cleveland Clinic Foundation, April 25, 2003

“When to Start HIV Therapy: Update on recent data”. Annual Nurse Practitioners Meeting Aurora, OH; April 26, 2003

“Challenges of Metabolic Complications in the Management of HIV Disease”. Annual Symposium of the Infectious Diseases Society of California, Indian Wells, CA. May 3, 2003

“Update on Long-Term Complications of HIV”. Medical Grand Rounds. North Bronx Hospital, NY, May 14, 2003

“HIV Update: Metabolic Complications in HIV”. Northeast OH Infectious Diseases Roundtable (CME), College Club of Cleveland, Cleveland Heights; May 21, 2003

“Revitalizing the Protease Inhibitor Class”. CME national teleconferences (3 hours) Sponsored by Rush-Presbyterian-St. Luke’s Medical Center. May 2003

“Adapting for Life: Managing long-term exposure to ART”. CME conference for Cleveland ID/HIV treaters (1 hour); July 24, 2003

“Managing long-term exposure to ART: Focus on morphologic changes and disorders of lipid and glucose metabolism”. National CME teleconferences (3 hours); August 2003

“Update on Metabolic Complications of HIV Therapy”; CME, Pennsylvania/Mid Atlantic AIDS Education and Training Center; Pennsylvania, PA; August 5, 2003

Post-International AIDS Society Update; “Metabolic Complications: what have we learned?” CME, College Club of Cleveland, Sept 10, 2003

“Update on the pathogenesis and management of metabolic complications of HIV” Infectious Diseases Conference; Harper Hospital/Detroit Medical Center, Detroit, MI September 22, 2003

“Latest update on metabolic complications of antiretroviral therapy” Infectious Diseases Conference; UCP Hahnemann University, September 25, 2003

“HIV Drug Toxicities and Management”; “Meet the Professor” – 2 sessions (CME); The 41th Annual Meeting of the Infectious Diseases Society of America, San Diego Oct 11 and Oct 12, 2003

“Managing long-term exposure to ART: Focus on mitochondrial toxicity and bone metabolism disorders”, National CME teleconferences (3 hours); November 2003

“Adapting for Life: Managing long-term exposure to ART”, CME conference for Michigan ID/HIV treaters (1 hour);

January 21, 2004

“Long term complications of antiretrovirals” Infectious Diseases Conference, Bronx VA Medical Center, Bronx, NY; April 8, 2004

“Lipoatrophy and Mitochondrial Toxicity: Truth Behind the Rumors”: Improving the Management of HIV Disease (CME). International AIDS Society-USA Seminar in Chicago, IL. May 3, 2004

“Lipoatrophy: Insight into Pathogenesis and Potential Therapies” (CME): University of Pennsylvania Infectious Diseases Conference. Philadelphia, PA, August 11, 2004

“NRTI backbone as determinant of Lipoatrophy Risk” (CME): Infectious Diseases Conference; UCP Hahnemann University, August 12, 2004

Co-Chair and Speaker; State of the Art: “Complications of HIV therapy”. Infectious Diseases Society of America Annual Meeting. Scheduled for October 2, 2004, Boston, MA